The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...